Toth Financial Advisory’s Madrigal Pharmaceuticals MDGL Stock Holding History

Toth Financial Advisory’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.07M	Hold	2,000	–	–	0.1%	140
2026 Q1	$1.05M	Hold	2,000	–	–	0.11%	130
2025 Q4	$1.16M	Buy	+2,000	New	+$1.02M	0.13%	125
2022 Q2	–	Sell	-20	Closed	-$2K	–	741
2022 Q1	$2K	Buy	+20	New	+$1.69K	﹤0.01%	628

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Toth Financial Advisory's MDGL Position: Q2 2026 in Review

Toth Financial Advisory held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2026 at 2,000 shares worth $1.07M. The position accounts for 0.1% of the portfolio, ranked #140.

Toth Financial Advisory first reported a position in MDGL in Q1 2022 and has held it in 4 quarters since. The position peaked at $1.16M in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Toth Financial Advisory held 2,000 shares of Madrigal Pharmaceuticals worth $1.07M as of Q2 2026.
Toth Financial Advisory left its Madrigal Pharmaceuticals share count unchanged in Q2 2026.
Madrigal Pharmaceuticals made up 0.1% of Toth Financial Advisory's portfolio in Q2 2026, its #140 holding.
Toth Financial Advisory first reported a position in Madrigal Pharmaceuticals in Q1 2022 and has held it in 4 quarters since.
Toth Financial Advisory's Madrigal Pharmaceuticals position peaked at $1.16M in Q4 2025.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Toth Financial Advisory's 13F filing for Q2 2026, filed 14 Jul 2026.